Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Familial Adenomatous Polyposis Clinical Trial

Official title:

Phase IIA Trial of Encapsulated Rapamycin (eRapa) to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04230499
• Other study ID #: EMT-FAP-001
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 18, 2021
• Est. completion date: February 2023

Study information

• Verified date: October 2022
• Source: Rapamycin Holdings Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.

Description:

Patients with FAP who are undergoing endoscopic surveillance will be given eRapa at one of three escalating doses/ schedules (0.5mg every other day, 0.5mg daily every other week, or 0.5mg daily) for 12 months with the aim of reducing polyp burden. Patients will serve as their own controls. Patients will be assessed with surveillance endoscopy at baseline, 6 months, and 12 months for change in polyp burden. Correlation between immune markers and clinical outcomes will be explored. This is a Phase IIa trial which will enroll at approximately 6-8 sites within the United States that have specialty expertise in FAP treatment and surveillance. The trial is anticipated to last approximately 24 months for treatment and follow up. The trial will enroll 30 patients with the genetic or clinical diagnosis of FAP. The clinical diagnosis includes individuals with 100 or more cumulative tubular adenomas throughout the colorectum. Patients must be undergoing surveillance for known FAP and can include those with intact colons as well as those who have undergone surgical therapy. For those patients who have undergone partial or total colectomy, they must have documented residual polyps in their rectum for which they are receiving active surveillance.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: February 2023
• Est. primary completion date: February 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Sign and date an informed consent form.

2. Stated willingness to comply with all study procedures and availability for the duration of the study.

3. Male or female, age at least 18 years at the time of consent.

4. Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC) germline mutation with or without family history, or with greater than a cumulative lifetime history of (>) 100 adenomas in large intestine and a family history of FAP, or FAP phenotype post colectomy for polyposis with a family history of FAP. Minimum number of polyps required for enrollment is 10.

5. Abilitiy to safely undergo endoscopy.

6. Ability to take oral medication and be willing to adhere to the eRapa regimen.

7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of eRapa administration.

8. A woman must agree not to breast feed or donate eggs (ova, oocytes) during the study and for a period of 12 weeks after the last administration of study drug.

Exclusion Criteria:

1. Risk-reduction surgery (colectomy or partial colectomy) within the 12 months prior to screening.

2. Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The use of 81 milligrams (mg) of aspirin a day or 650 mg of aspirin per week is allowed.

3. Treatment with other FAP-directed drug therapy (including NSAID [Non-steroidal anti-inflammatory drug] drugs), unless completes a 4 week washout period prior to enrollment.

4. Duodenum or colon/ rectum with high grade dysplasia or cancer on biopsy at screening.

5. Duodenal or colorectal polyp > 1 centimeter (cm) not excised at the screening evaluation.

6. Pregnancy or breast feeding.

7. Unable to provide consent or anticipated inability to attend appropriate follow-up visits.

8. Serum creatinine or measured/ calculated creatinine clearance (or glomerular filtration rate [GFR]) > 1.5 x ULN OR < 30mL/min for participants with creatine levels > 1.5 x institutional ULN. Bilirubin = 1.5 x ULN unless conjugated bilirubin = ULN; alkaline phosphatase > 5 x ULN; ALT/AST > 2 x ULN.

9. INR or PT or aPTT > 1.5 x institutional ULN unless the patient is receiving anticoagulant therapy as long as the PT or aPTT is within therapeutic range of intended use of anticoagulants.

10. Proteinuria > 1+ on urinalysis or > 1g/24h on 24h urine.

11. History of interstitial lung disease or non-infectious pneumonitis.

12. Immunosuppressed state (e.g., HIV, use of chronic steroids), active, uncontrolled infection.

13. On agents known to alter rapamycin metabolism significantly.

14. Concurrent involvement in other clinical trials specifically evaluating chemoprevention in FAP.

15. Patients with a colonic polyp burden too numerous to count.

Related Conditions & MeSH terms

• Adenomatous Polyposis Coli
• Colorectal Neoplasms
• Familial Adenomatous Polyposis
• Nasopharyngeal Neoplasms

Intervention

Drug:
• Encapsulated Rapamycin (eRapa)
eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Cleveland Clinic	Cleveland	Ohio
United States	Ohio State University Wexner Medical Center	Columbus	Ohio
United States	Mayo Clinic Arizona	Phoenix	Arizona
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Huntsman Cancer Institute and University of Utah	Salt Lake City	Utah
United States	UT Health San Antonio	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Rapamycin Holdings, Inc. dba Emtora Biosciences	LumaBridge

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Explore correlation between immune markers influenced by mTOR inhibition and clinical outcomes	Immunologic response will be measured and will include overall assessment of T cell phenotype and function.	Following patients out to 12 months.
Primary	Frequency and severity of adverse events associated with low dose eRapa in FAP patients	Safety and tolerability of eRapa as determined by graded toxicity assessed throughout the trial per CTCAE v5.0.	All adverse events with start dates occurring any time after informed consent is obtained until 7 days (for non-serious adverse events) or 30 days (for serious adverse events) after the last day of study participation will be recorded.
Primary	Determine the Recommended Phase 2 Dose (RP2D)	The Recommended Phase 2 Dose (RP2D) will be determined by examining and analyzing safety/ adverse events as reflected by Outcome 1, dose delays, dose reductions, withdrawal of treatment secondary to low-grade toxicities, and serum pharmacokinetic monitoring.	After informed consent is obtained up to 30 days after the last day of study participation.
Primary	Efficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.	Percentage change from baseline in colorectal polyp burden as measure by endoscopy at 6 months.	Time for each patient is baseline to 6 months.
Secondary	Clinical effect of eRapa on polyp burden.	Percentage change from baseline in colorectal polyp burden at 12 months.	Following patients out to 12 months.
Secondary	Clinical effect of eRapa on International Society for Gastrointestinal Hereditary Tumors Stage.	Change from baseline in International Society for Gastrointestinal Hereditary Tumors Stage at 6 and 12 months.	Following patients out to 6 and 12 months.
Secondary	Clinical effect of eRapa on Spigelman Stage Score.	Change from baseline in Spigelman Stage Score at 6 and 12 months in patients with polyps at baseline on EGD. The Spigelman scoring system assigns points (0, 1, 2, or 3) based on number of adenomas, size (mm), histology, and dysplasia. The scoring ranges from 0 to 12 points. A higher score is a worse outcome.	Following patients out to 6 and 12 months.
Secondary	Clinical effect of eRapa on duodenal polyp number and burden.	Percentage change from baseline in the duodenal polyp number and burden at 6 and 12 months in patients with polyps at baseline on EGD.	Following patients out to 6 and 12 months.